COVID-19 is a critical pandemic that affected communities around the world, and there is currently no specific drug treatment for it. The virus enters the human cells via spikes and induces cytokine production and finally arrests the cell cycle. Ivermectin shows therapeutic potential for treating COVID-19 infection based on in vitro studies. Docking studies have shown a strong affinity between Ivermectin and some virulence factors of COVID-19. Notably, clinical evidence has demonstrated that Ivermectin with usual doses is effective by both the prophylactic and therapeutic approaches in all phases of the disease. Ivermectin inhibits both the adhesion and replication of the virus. Local therapy of the lung with Ivermectin or combination therapy may get better results and decrease the dose of the drug.
TaguchiYHTurkiT. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction.PLoS ONE2020;15:e0238907
2.
CortegianiAIngogliaGIppolitoMGiarratanoAEinavS. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.J Crit Care2020;57:279–83
3.
NaqviAATFatimaKMohammadTFatimaUSinghIKSinghAAtifSMHariprasadGHasanGMHassanMI. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach.Biochim Biophys Acta Mol Basis Dis2020;866:165878
4.
Momtazi-BorojeniAABanachMReinerŽPirroMBianconiVAl-RasadiKSahebkarA. Interaction between coronavirus S-protein and human ACE2: hints for exploring efficient therapeutic targets to treat COVID-19.Angiology2021;72:122–30
5.
SungnakWHuangNBécavinCBergMQueenRLitvinukovaMTalavera-LópezCMaatzHReichartDSampaziotisFWorlockKBYoshidaMBarnesJL, HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.Nat Med2020;26:681–7
6.
CoutardBValleCde LamballerieXCanardBSeidahNGDecrolyE. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.Antiviral Res2020;176:104742
7.
LiWMooreMJVasilievaNSuiJWongSKBerneMASomasundaranMSullivanJLLuzuriagaKGreenoughTC. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.Nature2003;426:450–4
8.
HammingITimensWBulthuisMLLelyATNavisGvan GoorH. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.J Pathol2004;203:631–7
9.
XiaSLanQSuSWangXXuWLiuZZhuYWangQLuLJiangS. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.Signal Transduct Target Ther2020;5:92
AnandPPuranikAAravamudanMVenkatakrishnanASoundararajanV. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.eLife2020;9:e58603
13.
BouhaddouMMemonDMeyerBWhiteKMRezeljVVMarreroMCPolaccoBJMelnykJEUlfertsSKaakeRM. The global phosphorylation landscape of SARS-CoV-2 infection.Cell2020;182:685–712.e19
14.
RomagnoliSPerisADe GaudioARGeppettiP. SARS-CoV-2 and COVID-19: from the bench to the bedside.Physiol Rev2020;100:1455
15.
CrumpA. Ivermectin: enigmatic multifaceted “wonder” drug continues to surprise and exceed expectations.J Antibiot2017;70:495–505
16.
ŌmuraSShiomiK. Discovery, chemistry, and chemical biology of microbial products.Pure Appl Chem2007;79:581–91
JuarezMSchcolnik-CabreraADueñas-GonzalezA. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.Am J Cancer Res2018;8:317–31
19.
IntuyodKHahnvajanawongCPinlaorPPinlaorS. Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro.Anticancer Res2019;39:4837–43
20.
RazazanANicastroJSlavcevRBaratiNArabAMosaffaFJaafariMRBehravanJ. Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice.Sci Rep2019;9:2221
21.
BaratiNMomtazi-BorojeniAAMajeedMSahebkarA. Potential therapeutic effects of curcumin in gastric cancer.J Cell Physiol2019;234: 2317–28
22.
NaghibiLYazdaniMMomtazi-BorojeniAARazazanAShariatSMansourianMArabABaratiNArabsalmaniMAbbasiASaberiZBadieeAJalaliSAJaafariMR. Preparation of nanoliposomes containing HER2/neu (P5+ 435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.PLoS ONE2020;15:e0243550
23.
LloydAEHoneyBLJohnBMCondrenM. Treatment options and considerations for intestinal helminthic infections.J Pharm Technol2014;30:130–9
24.
CampbellSSoman-FaulknerK. Antiparasitic drugs. Treasure Island, FL: StatPearls Publishing, 2022
25.
RezaHAMRrezaGNastaranBMousaM. Renal hydatid cyst; a rare infectious disease.Oxf Med Case Reports2019;2019:omz011
26.
Motevalli HaghiSMNajmMFakharMGholamiSMotevalliHaghiS. Prevalence of Enterobius vermicularis infection among kindergartens of Sari and Babol cities during 2011.J Mazandaran Univ Med Sci2013;22:240–2
27.
HeidaryFGharebaghiR. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.J Antibiot2020;73:593–602
28.
ChaccourCHammannFRamón-GarcíaSRabinovichNR. Ivermectin and COVID-19: keeping rigor in times of urgency.Am J Trop Med Hyg2020;102:1156–7
29.
GuzzoCAFurtekCIPorrasAGChenCTippingRClineschmidtCMSciberrasDGHsiehJYLasseterKC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.J Clin Pharmacol2002;42:1122–33
30.
BagheriEAbnousKFarzadSATaghdisiSMRamezaniMAlibolandiM. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.Life Sci2020;261:118369
31.
SmitMROchomoEOAljayyoussiGKwambaiTKAbong’oBOChenTBousemaTSlaterHCWaterhouseDBayohNMGimnigJESamuelsAMDesaiMRPhillips-HowardPAKariukiSKWangDWardSATer KuileFO. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.Lancet Infect Dis2018;18:615–26
32.
VoraAAroraVKBeheraDTripathySK. White paper on Ivermectin as a potential therapy for COVID-19.Indian J Tuberc2020;67:448–51
33.
SharunKDhamaKPatelSKPathakMTiwariRSinghBRSahRBonilla- AldanaDKRodriguez-MoralesAJLeblebiciogluH. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.Ann Clin Microbiol Antimicrob2020;19:23
BanerjeeKNandyMDalaiCKAhmedSN. The battle against COVID 19 pandemic: what we need to know before we “test fire” Ivermectin.Drug Res2020;70:337–40
36.
WagstaffKMSivakumaranHHeatonSMHarrichDJansDA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.Biochem J2012;443:851–6
37.
LundbergLPinkhamCBaerAAmayaMNarayananAWagstaffKMJansDAKehn-HallK. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication.Antiviral Res2013;100:662–72
38.
GötzVMagarLDornfeldDGieseSPohlmannAHöperDKongB-WJansDABeerMHallerO. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import.Sci Rep2016;6:23138
39.
MastrangeloEPezzulloMDe BurghgraeveTKapteinSPastorinoBDallmeierKde LamballerieXNeytsJHansonAMFrickDNBolognesiMMilaniM. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.J Antimicrob Chemother2012;67:1884–94
40.
LvCLiuWWangBDangRQiuLRenJYanCYangZWangX. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo.Antiviral Res2018;159:55–62
41.
YangSNYAtkinsonSCWangCLeeABogoyevitchMABorgNAJansDA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.Antiviral Res2020;177:104760
42.
CalyLDruceJDCattonMGJansDAWagstaffKM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res2020;178:104787
43.
PareekRSaxenaRSaxenaV. “Ivermectin”—a key in the bunch of keys to unlock the other activities including educational institutions in COVID-19 pandemic.Int J Sci Res2020;9:939–50
44.
YavuzSÜnalS. Antiviral treatment of COVID-19.Turk J Med Sci2020;50:611–9
45.
DiNicolantonioJJBarrosoJMcCartyM. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.Open Heart2020;7:e001350
46.
SchmithVDZhouJLohmerLR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19.Clin Pharmacol Ther2020;108:762–5
47.
FormigaFRLeblancRde Souza RebouçasJFariasLPde OliveiraRNPenaL. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.J Control Release2021;329:758–61
48.
BrayMRaynerCNoëlFJansDWagstaffK. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses.Antiviral Res2020;178:104805
RajterJCShermanMFattehNVogelFSacksJRajterJ-J. ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19.medRxiv2020, https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2
Szente FonsecaSNde Queiroz SousaAWolkoffAGMoreiraMSPintoBCValente TakedaCFRebouçasEVasconcellos AbdonAPNascimentoALARischHA. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: comparative analysis.Travel Med Infect Dis2020;38:101906
53.
López-MedinaELópezPHurtadoICDávalosDMRamirezOMartínezEDíazgranadosJAOñateJMChavarriagaHHerreraS. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial.JAMA2021;325:1426–35
54.
DiNicolantonioJJBarroso-ArandaJMcCartyMF. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.Open Heart2021;8:e001655
55.
AudusKLKnaubSRGuillotFLSchaefferJM. The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells.Vet Res Commun1992;16:365–77
56.
LifschitzAVirkelGSallovitzJSutraJGaltierPAlvinerieMLanusseC. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle.Vet Parasitol2000;87:327–38
57.
ChoudhuryADasNCPatraRBhattacharyaMGhoshPPatraBCMukherjeeS. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach.Future Virol2021;16:277–91
58.
BelloM. Elucidation of the inhibitory activity of Ivermectin with host nuclear importin α and several SARS-CoV-2 targets.J Biomol Struct Dyn. Epub ahead of print 10 April 2021. DOI: 10.1080/07391102.2021.1911857
59.
SahaJKRaihanM. The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.Struct Chem2021;32:1985–92
60.
LehrerSRheinsteinPH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.In Vivo2020;34:3023–6
61.
KalhorHSadeghiSAbolhasaniHKalhorRRahimiH. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.J Biomol Struct Dyn2022;40:1299–315
62.
LowZYYipAJWLalSK. Repositioning Ivermectin for Covid-19 treatment: molecular mechanisms of action against SARS-CoV-2 replication.Biochim Biophys Acta Mol Basis Dis2022;1868:166294
63.
RomanoMRuggieroASquegliaFMagaGBerisioR. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping.Cells2020;9:1267
64.
GaoYYanLHuangYLiuFZhaoYCaoLWangTSunQMingZZhangL. Structure of the RNA-dependent RNA polymerase from COVID-19 virus.Science2020;368:779–82
65.
Sen GuptaPSBiswalSPandaSKRayAKRanaMK. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin.J Biomol Struct Dyn2020;40:2217–26
66.
ModyVHoJWillsSMawriALawsonLEbertMCFortinGMRayalamSTavalS. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.Commun Biol2021;4:93
67.
AnandKZiebuhrJWadhwaniPMestersJRHilgenfeldR. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.Science2003;300:1763–7
68.
NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaS. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors.J Theor Biol2008;254:861–7
69.
Jamalipour SoufiGIravaniS. Potential inhibitors of SARS-CoV-2: recent advances.J Drug Target2021;29:349–64
70.
SilvestriniLBelhajNComezLGerelliYLauriaALiberaVMarianiPMarzulloPOrtoreMGPalumbo PiccionelloA. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.Sci Rep2021;11:9283
71.
LittlerDRGullyBSColsonRNRossjohnJ. Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9.iScience2020;23:101258
72.
ZaidiAKDehgani-MobarakiP. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review.J Antibiot2022;75:60–71
73.
ParkAIwasakiA. Type I and type III interferons–induction, signaling, evasion, and application to combat COVID-19.Cell Host Microbe2020;27:870–8
74.
WangCSunMYuanXJiLJinYCardonaCJXingZ. Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation.J Biol Chem2017;292:10262–74
75.
SethCMasCConodAMuellerJSiemsKKuciakMBorgesIRuiziAltabaA. Long-lasting WNT-TCF response blocking and epigenetic modifying activities of Withanolide F in human cancer cells.PLoS ONE2016;11:e0168170
76.
GuptaKKXuZCastellinoFJPloplisVA. Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4.Biochem Biophys Res Commun2016;477:503–8
77.
MatsuyamaTKubliSPYoshinagaSKPfefferKMakTW. An aberrant STAT pathway is central to COVID-19.Cell Death Differ2020;27:3209–25
78.
YangDChuHHouYChaiYShuaiHLeeAC-YZhangXWangYHuBHuangX. Attenuated interferon and proinflammatory response in SARS-CoV-2–infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation.J Infect Dis2020;222:734–45
79.
KonnoYKimuraIUriuKFukushiMIrieTKoyanagiYSauterDGiffordRJNakagawaSSatoK. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant.Cell Rep2020;32:108185
80.
AluwiharePMungerJS. What the lung has taught us about latent TGF-β activation.Am J Respir Cell Mol Biol2008;39:499–502
81.
HanSMallampalliRK. The acute respiratory distress syndrome: from mechanism to translation.J Immunol2015;194:855–60
82.
DouQChenH-NWangKYuanKLeiYLiKLanJChenYHuangZXieN. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer.Cancer Res2016;76:4457–69
83.
de MeloGDLazariniFLarrousFFeigeLKornobisELevalloisSMarchioAKergoatLHardyDCokelaerT. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin.EMBO Mol Med2021;13:e14122
84.
ZhangXSongYCiXAnNJuYLiHWangXHanCCuiJDengX. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.Inflamm Res2008;57:524–9
85.
ZhangXSongYXiongHCiXLiHYuLZhangLDengX. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages.Int Immunopharmacol2009;9:354–9
86.
ViktorovAV. Ivermectin inhibits activation of Kupffer cells induced by lipopolysaccharide toxin.Antibiot Khimioter2003;48:3–6
87.
CiXLiHYuQZhangXYuLChenNSongYDengX. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway.Fundam Clin Pharmacol2009;23:449–55
88.
WheelerMStachlewitzRFYamashinaSIkejimaKMorrowALThurmanRG. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production.FASEB J2000;14:476–84
89.
McCartyMFIloki-AssangaSLujanLMLDiNicolantonioJJ. Activated glycine receptors may decrease endosomal NADPH oxidase activity by opposing ClC-3-mediated efflux of chloride from endosomes.Med Hypotheses2019;123:125–9
90.
ShanQHaddrillJLLynchJW. Ivermectin, an unconventional agonist of the glycine receptor chloride channel.J Biol Chem2001;276:12556–64
91.
LynaghTWebbTIDixonCLCromerBALynchJW. Molecular determinants of ivermectin sensitivity at the glycine receptor chloride channel.J Biol Chem2011;286:43913–24
92.
WangQLynchJW. A comparison of glycine-and ivermectin-mediated conformational changes in the glycine receptor ligand-binding domain.Int J Biochem Cell Biol2012;44:335–40
93.
WheelerMIkejemaKEnomotoNStacklewitzRSeabraVZhongZYinMSchemmerPRoseMRusynI. Glycine: a new anti-inflammatory immunonutrient.Cel Mol Life Sci1999;56:843–56
94.
CalyLWagstaffKMJansDA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?Antiviral Res2012;95:202–6
95.
YangSNAtkinsonSCFraserJEWangCMaherBRomanNForwoodJKWagstaffKMBorgNAJansDA. Novel flavivirus antiviral that targets the host nuclear transport importin α/β1 heterodimer.Cells2019;8:281
96.
AzamFTabanIMEidEEIqbalMAlamOKhanSMahmoodDAnwarMJKhalilullahHKhanM. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α.J Biomol Struct Dyn2022;40:2851–64
97.
AzamFAlabdullahNHEhmedatHMAbulifaARTabanIUpadhyayulaS. NSAIDs as potential treatment option for preventing amyloid β toxicity in Alzheimer’s disease: an investigation by docking, molecular dynamics, and DFT studies.J Biomol Struct Dyn2018;36:2099–117
98.
SmithTGRobbinsPARatcliffePJ. The human side of hypoxia-inducible factor.Br J Haematol2008;141:325–34
99.
WilkinsSEAbboudMIHancockRLSchofieldCJ. Targeting protein–protein interactions in the HIF system.ChemMedChem2016;11:773–86
100.
GilmanNV. Analyses of the 2019 Nobel Prize in physiology or medicine: molecular machinery for cellular oxygen level response.Sci Technol Libr2020;39:1–27
101.
SerebrovskaZOChongEYSerebrovskaTVTumanovskaLVXiL. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets.Acta Pharmacol Sin2020;41:1539–46
102.
MorrisDRQuYAgrawalAGarofaloRPCasolaA. HIF-1α modulates core metabolism and virus replication in primary airway epithelial cells infected with respiratory syncytial virus.Viruses2020;12:1088
103.
GolanMMabjeeshNJ. SEPT9_i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation.Cell Cycle2013;12:2297–308
104.
RussoPBonassiSGiacconiRMalavoltaMTominoCMaggiF. COVID-19 and smoking: is nicotine the hidden link?Eur Respir J2020;55:2001116
105.
LeungJMYangCXSinDD. COVID-19 and nicotine as a mediator of ACE-2.Eur Respir J2020;55:2001261
106.
OldsJLKabbaniN. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?FEBS J2020;287: 3651–5
107.
KashyapVKDhasmanaAMasseyAKotnalaSZafarNJaggiMYallapuMMChauhanSC. Smoking and COVID-19: adding fuel to the flame.Int J Mol Sci2020;21:6581
108.
KrauseRMBuissonBBertrandSCorringerP-JGalziJ-LChangeuxJ-PBertrandD. Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor.Mol Pharmacol1998;53:283–94
109.
ChaccourCAbizandaGIrigoyen-BarrioÁCasellasAAldazAMartínez-GalánFHammannFGilAG. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.Sci Rep2020;10:17073
